Cargando…

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Traditional clinicopathological features do not predict which patients will develop chemotherapy resistance. The TP53 gene is frequently altered in ovarian cancer but its prognostic implications are controversial. Little is known on the impact of TP53-downstream genes on prognosis. Using molecular a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuyer, M, Burg, M E L van der, Henzen-Logmans, S C, Fieret, J H, Klijn, J G M, Look, M P, Foekens, J A, Stoter, G, Berns, E M J J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375252/ https://www.ncbi.nlm.nih.gov/pubmed/11720475 http://dx.doi.org/10.1054/bjoc.2001.2101

Ejemplares similares

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
por: Schuyer, M., et al.
Publicado: (1996)

Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.
por: Henzen-Logmans, S. C., et al.
Publicado: (1992)

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
por: Berns, E. M., et al.
Publicado: (1998)

Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.
por: Burger, H., et al.
Publicado: (1998)

Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as prognostic marker
por: Chia, S-J, et al.
Publicado: (2000)

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
por: Kupryjańczyk, J, et al.
Publicado: (2003)

The Action of Bax and Bcl-2 on T Cell Selection
por: Williams, Owen, et al.
Publicado: (1998)

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.
por: Nooter, K., et al.
Publicado: (1997)

The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma
por: Ghanem, M A, et al.
Publicado: (2001)

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status
por: Mirjolet, J-F, et al.
Publicado: (2000)

Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX
por: Nehls, O, et al.
Publicado: (2007)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia
por: Vucicevic, Ksenija, et al.
Publicado: (2016)

Expression of Apoptotic Markers Bcl-2 and Bax in the Vascular Wall
por: Klimentova, E.A., et al.
Publicado: (2021)

Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax
por: Billen, Lieven P, et al.
Publicado: (2008)

Stromal influences on breast cancer cell growth.
por: van Roozendaal, C. E., et al.
Publicado: (1992)

miR-21 regulates ischemic neuronal injury via the p53/Bcl-2/Bax signaling pathway
por: Yan, Honglin, et al.
Publicado: (2021)

cBid, Bax and Bcl-xL exhibit opposite membrane remodeling activities
por: Bleicken, S, et al.
Publicado: (2016)

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Aberrant immunoexpression of p53 tumour-suppressor and Bcl-2 family proteins (Bcl-2 and Bax) in ameloblastomas and odontogenic keratocysts
por: Escobar, Enrico, et al.
Publicado: (2023)

Opposite role of Bax and BCL-2 in the anti-tumoral responses of the immune system
por: Bougras, Gwenola, et al.
Publicado: (2004)

Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)
por: Punt, C. J., et al.
Publicado: (1990)

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma
por: Kang, Qiang, et al.
Publicado: (2018)

Effect of L-carnitine on the expression of the apoptotic genes Bcl-2 and Bax
por: Vardiyan, Reyhane, et al.
Publicado: (2020)

Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax
por: Hockings, C, et al.
Publicado: (2015)

Bax/Bak activation in the absence of Bid, Bim, Puma, and p53
por: Zhang, J, et al.
Publicado: (2016)

Apoptosis and cell cycle aberrations in epithelial odontogenic lesions: An evidence by the expression of p53, Bcl-2 and Bax
por: Tenório, Jefferson-da Rocha, et al.
Publicado: (2018)

Early and late apoptosis protein expression (Bcl-2, BAX and p53) in traumatic brachial plexus injury
por: Suroto, Heri, et al.
Publicado: (2021)

Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance.
por: Williamson, K. E., et al.
Publicado: (1998)

Expression of Apoptosis‐regulating Proteins Bcl‐2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma
por: Meichner, K., et al.
Publicado: (2016)

Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis
por: Fan, Yichao, et al.
Publicado: (2014)

Regulated Targeting of BAX to Mitochondria
por: Goping, Ing Swie, et al.
Publicado: (1998)

Puma strikes Bax
por: Letai, Anthony
Publicado: (2009)

Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study.
por: Koshida, Y., et al.
Publicado: (1997)

The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells
por: Han, Ji-Youn, et al.
Publicado: (1999)

p27 Deficiency Cooperates with Bcl-2 but Not Bax to Promote T-Cell Lymphoma
por: Cheng, Ningli, et al.
Publicado: (2008)

Bcl-xl does not have to bind Bax to protect T cells from death
por: Liu, Xinqi, et al.
Publicado: (2006)

Expression of Bcl-2 and Bax in Mouse Renal Tubules during Kidney Development
por: Song, Xiao-Feng, et al.
Publicado: (2012)

BCL-2 and Bax Expression in Skin Flaps Treated with Finasteride or Azelaic Acid
por: Ayatollahi, Seyyed Abdulmajid, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c2i4o8f7qqsoa4cg1c041fotiu